The objective of this proposal is to form a core facility for AIDS-related molecular biology with emphasis on expression and production of viral or cellular proteins for use in AIDS research. We have extensive expertise in application of several recombinant systems for expression of proteins in bacteria, established culture cell lines, and insect cell systems, which have been previously used by our laboratories to produce viral proteins of HIV-1, and HIV-2 and SIV, cellular transcription factors, growth factors, and cytokines. In addition, we have a great deal of experience in the use of various procedures for purifying individual protein compartments from culture media for cell lysates. Particular importance will be laced on use of purification procedures that will yield antigens in their native antigenic configuration. The expressed proteins will be provided to CFAR investigators for ongoing projects in vaccine development, viral pathogenesis, structure-function studies, and other research programs. In addition to providing a facility for protein production and purification, the facility will provide training to CFAR investigators in basic molecular biology techniques related to gene expression. These include training of new investigators in basic molecular biology techniques related to gene expression. These include training of new investigations in basic procedures such as plasmid preparation, transfection, and protein purification. Finally, this Core Facility will provide a repository for expression vectors and cells which will be useful for expression of cloned genes, as well as a repository of plasmids containing genes of HIV, SIV, viral receptors and co-receptors, and other related genes of interest. The overall objective is therefore to facilitate interdisciplinary research by providing essential expertise in molecular biology with particular emphasis on expression of genes of interest for AIDS research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA012121-02
Application #
6201662
Study Section
Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Thomas, Ajit G; Bodner, Amos; Ghadge, Ghanashyam et al. (2009) GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity. J Neurovirol 15:449-57
Haubrich, Richard H; Riddler, Sharon A; DiRienzo, A Gregory et al. (2009) Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23:1109-18
Pillai, Vinod Bhaskara; Hellerstein, Michael; Yu, Tianwei et al. (2008) Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26:1136-41
Riddler, Sharon A; Haubrich, Richard; DiRienzo, A Gregory et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358:2095-106
Sadagopal, Shanmugalakshmi; Amara, Rama Rao; Kannanganat, Sunil et al. (2008) Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 82:4149-53
Lai, Lilin; Vodros, Dalma; Kozlowski, Pamela A et al. (2007) GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-67

Showing the most recent 10 out of 42 publications